Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Profound Medical Corp. - common stock (NQ:PROF)

7.160 -0.040 (-0.56%)

Streaming Delayed Price Updated: 10:03 AM EDT, May 15, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	6,701
Open	7.240
Bid (Size)	7.100 (3,600)
Ask (Size)	7.270 (300)
Prev. Close	7.200
Today's Range	7.100 - 7.240
52wk Range	3.760 - 8.950
Shares Outstanding	20,208,948
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches

Today 6:30 EDT

From Telix Pharmaceuticals Limited

Via GlobeNewswire

Profound to Showcase TULSA-PRO®, the TULSA Procedure™ and the Future of iMRI at AUA2026

May 14, 2026

Company to explore the potential of integrating TULSA-PRO with PSMA PET molecular imaging technologies to enhance ablation planning and monitoring

From Profound Medical Corp.

Via GlobeNewswire

Performance

YTD	-6.5%	-6.5%
1 Month	+14.4%	+14.4%
3 Month	+14.9%	+14.9%
6 Month	+12.8%	+12.8%
1 Year	+77.2%	+77.2%

More News

Profound Medical Q1 Earnings Call Highlights ↗

May 08, 2026

Via MarketBeat

Profound Medical Reports Strong First Quarter 2026 Financial Results

May 07, 2026

From Profound Medical Corp.

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF

April 21, 2026

From Pomerantz LLP

Via GlobeNewswire

Profound Medical to Release First Quarter 2026 Financial Results on May 7 – Conference Call to Follow

April 16, 2026

From Profound Medical Corp.

Via GlobeNewswire

Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference

April 14, 2026

From Profound Medical Corp.

Via GlobeNewswire

Incision-Free, MRI-Guided Prostate Treatment with Profound’s TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting

April 01, 2026

From Profound Medical Corp.

Via GlobeNewswire

Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone

March 27, 2026

From Profound Medical Corp.

Via GlobeNewswire

CAPTAIN Trial Comparing Profound’s MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence

March 13, 2026

From Profound Medical Corp.

Via GlobeNewswire

Profound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13; Participate in ROTH Investor Conference on March 22-24

March 09, 2026

From Profound Medical Corp.

Via GlobeNewswire

Here are the top movers in Friday's session. ↗

March 06, 2026

Via Chartmill

Profound Medical Reports Fourth Quarter and Full Year 2025 Financial Results

March 05, 2026

From Profound Medical Corp.

Via GlobeNewswire

Profound Medical to Release Fourth Quarter and Full Year 2025 Financial Results on March 5th – Conference Call to Follow

February 12, 2026

From Profound Medical Corp.

Via GlobeNewswire

Profound Medical Honored with INOVAIT’s 2025–2026 Mount Logan Award Recognizing the TULSA Procedure™ for Prostate Disease

February 12, 2026

From Profound Medical Corp.

Via GlobeNewswire

Profound Medical Announces Upcoming Investor Events

January 27, 2026

From Profound Medical Corp.

Via GlobeNewswire

PRO FAMILIA and Profound Medical Celebrate 500 Sonalleve® Procedures, Expanding Access to Incision-Free Care for Women’s Health

February 05, 2026

From Profound Medical Corp.

Via GlobeNewswire

Mount Sinai Becomes First in Metro New York to Deliver Incision-Free, MRI-Guided Prostate Treatment with TULSA-PRO®

January 15, 2026

From Profound Medical Corp.

Via GlobeNewswire

Profound Surpasses 2025 TULSA-PRO® Installed Base Goal

January 12, 2026

From Profound Medical Corp.

Via GlobeNewswire

Johns Hopkins Medicine Treats First Commercial TULSA-PRO® Case

January 06, 2026

From Profound Medical Corp.

Via GlobeNewswire

InvestorNewsBreaks – Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) Closes $36 Million Registered Direct Offering

December 31, 2025

Via Investor Brand Network

Profound Medical Corp. Announces Closing of Private Placement

December 30, 2025

From Profound Medical Corp.

Via GlobeNewswire

Profound Medical Corp. Announces Upsize of Private Placement

December 24, 2025

From Profound Medical Corp.

Via GlobeNewswire

Profound Medical Corp. Closes $36 Million Registered Direct Offering; Expects to Complete Subsequent Private Placement On or Before December 30th

December 23, 2025

From Profound Medical Corp.

Via GlobeNewswire

Profound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private Placement

December 19, 2025

From Profound Medical Corp.

Via GlobeNewswire

Frequently Asked Questions

Is Profound Medical Corp. - common stock publicly traded?

Yes, Profound Medical Corp. - common stock is publicly traded.

What exchange does Profound Medical Corp. - common stock trade on?

Profound Medical Corp. - common stock trades on the Nasdaq Stock Market

What is the ticker symbol for Profound Medical Corp. - common stock?

The ticker symbol for Profound Medical Corp. - common stock is PROF on the Nasdaq Stock Market

What is the current price of Profound Medical Corp. - common stock?

The current price of Profound Medical Corp. - common stock is 7.160

When was Profound Medical Corp. - common stock last traded?

The last trade of Profound Medical Corp. - common stock was at 05/15/26 10:03 AM ET

What is the market capitalization of Profound Medical Corp. - common stock?

The market capitalization of Profound Medical Corp. - common stock is 144.70M

How many shares of Profound Medical Corp. - common stock are outstanding?

Profound Medical Corp. - common stock has 145M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.